Biotechnology Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1RNXT RenovoRx
4837.76
 0.18 
 12.93 
 2.32 
2PTCT PTC Therapeutics
1743.27
 0.11 
 3.24 
 0.36 
3CRBP Corbus Pharmaceuticals Holding
925.61
 0.16 
 33.32 
 5.18 
4MDXG MiMedx Group
902.47
 0.03 
 2.62 
 0.07 
5IMNM ImmunomeInc
229.95
 0.30 
 7.06 
 2.09 
6MDGL Madrigal Pharmaceuticals
225.59
 0.05 
 4.79 
 0.22 
7AGEN Agenus Inc
218.61
(0.01)
 7.39 
(0.08)
8GALT Galectin Therapeutics
207.7
 0.00 
 3.68 
 0.02 
9ALNY Alnylam Pharmaceuticals
142.92
(0.05)
 2.61 
(0.14)
10GMDA Gamida Cell
128.12
 0.06 
 8.40 
 0.47 
11BBIO BridgeBio Pharma
123.68
 0.07 
 3.87 
 0.25 
12QSAM Qsam Biosciences
110.97
 0.02 
 5.37 
 0.11 
13HARP Harpoon Therapeutics
108.14
 0.14 
 14.70 
 2.00 
14CING Cingulate
105.12
 0.01 
 26.20 
 0.29 
15OCEA Ocean Biomedical
100.67
 0.12 
 24.99 
 3.00 
16PROK ProKidney Corp
91.32
 0.05 
 6.42 
 0.32 
17FENC Fennec Pharmaceuticals
84.82
 0.03 
 2.33 
 0.08 
18MOR MorphoSys AG ADR
77.01
 0.20 
 9.42 
 1.86 
19ESPR Esperion Therapeutics
74.89
 0.15 
 6.84 
 1.05 
20CHRS Coherus BioSciences
73.19
 0.03 
 6.81 
 0.20 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.